Bottom line
PVEX vs VPMCX: the short answer
PVEX (TrueShares ConVequity ETF) and VPMCX (Vanguard PRIMECAP Fund) are both etfs.
VPMCX is cheaper at 0.35% vs 0.82% — a difference of $47 a year per $10,000 invested.
Updated Nov 19, 2026
PVEX vs VPMCX side by side
| PVEX | VPMCX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Elevation | Vanguard |
| Category | Large Blend | Large Blend |
| Expense ratio | 0.82% | 0.35% |
| Annual cost per $10k | $82 | $35 |
| 10-yr cost on $10k (prospectus) | $1,013 | $443 |
| Max front load | None | 0% |
| 12b-1 fee | 0% | 0% |
| 1-yr return | — | +29.9% |
| 5-yr return (annualized) | — | +14.3% |
| 10-yr return (annualized) | — | +15.2% |
| Best quarter | — | +17.3% |
| Worst quarter | — | −20.2% |
| Net assets (fund) | $55.7M | $96.1B |
| Number of holdings | 105 | 173 |
| Portfolio turnover | 15% | 11% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
PVEX and VPMCX share none of their top holdings.
PVEX top 10
- State Street SPDR Portfolio Sh — 26.17%
- Shreya Acquisition Group — 8.60%
- Treasury Bill — 8.01%
- Treasury Bill — 7.94%
- Treasury Bill — 7.85%
- Treasury Bill — 7.77%
- Janus Henderson AAA CLO ETF — 6.53%
- Roman DBDR Acquisition Corp II — 6.46%
- APEX Tech Acquisition Inc — 3.49%
- The Options Clearing Corp — 2.88%
VPMCX top 10
- Micron Technology Inc — 13.50%
- Intel Corp — 6.80%
- Eli Lilly & Co — 6.76%
- KLA Corp — 3.85%
- Alphabet Inc — 3.52%
- AstraZeneca PLC — 2.35%
- NVIDIA Corp — 2.33%
- Amazon.com Inc — 2.05%
- Tesla Inc — 1.89%
- Biogen Inc — 1.88%
FAQ
What is the difference between PVEX and VPMCX?
PVEX (TrueShares ConVequity ETF) and VPMCX (Vanguard PRIMECAP Fund) are both etfs. VPMCX is cheaper at 0.35% vs 0.82% — a difference of $47 a year per $10,000 invested.
Which is cheaper, PVEX or VPMCX?
VPMCX has the lower expense ratio (0.35%).
Should I own both PVEX and VPMCX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.